Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:03:16.817Z.
Calculation as of: 2026-10-06T15:03:16.817Z.
Quote observation: 2026-10-06T15:00:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f7cc47a755cd2bcf7eb9f00e67443ad18d7371fac0edeabf5a8ccfa0f762fc55
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2021-08-10.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
PRICE/OCF RATIO AVG TTM
N/A
PRICE/OCF RATIO AVG 3Y
N/A
PRICE/OCF RATIO AVG 5Y
N/A
PRICE/OCF RATIO AVG 10Y
N/A
PRICE/OCF RATIO AVG 15Y
N/A
PRICE/OCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$1.02B
Price/OCF Ratio
11.93
TTM Avg
14.48
3Y Avg
14.58
5Y Avg
15.53
Market Cap
$1.03B
Price/OCF Ratio
15.87
TTM Avg
16.75
3Y Avg
16.75
5Y Avg
16.75
Market Cap
$1.00B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$998.66M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$992.77M
Price/OCF Ratio
72.52
TTM Avg
103.87
3Y Avg
103.87
5Y Avg
103.87
Market Cap
$1.05B
Price/OCF Ratio
24.59
TTM Avg
16.06
3Y Avg
17.84
5Y Avg
17.84
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | $1.02B | N/A | N/A | N/A | N/A |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.02B | 11.93 | 14.48 | 14.58 | 15.53 |
| Immatics N.V. (IMTX)vs › | $1.01B | N/A | 78.34 | 28.91 | 23.78 |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | 15.87 | 16.75 | 16.75 | 16.75 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $1.00B | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $998.66M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $992.77M | 72.52 | 103.87 | 103.87 | 103.87 |
| Aktis Oncology, Inc. (AKTS)vs › | $991.19M | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.05B | 24.59 | 16.06 | 17.84 | 17.84 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.06B | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/OCF RATIO |
|---|---|
| 2021-08-10 | 618.96 |
| 2021-08-09 | 611.05 |
| 2021-08-06 | 587.34 |
| 2021-08-05 | 668.69 |
| 2021-08-04 | 653.65 |
| 2021-08-03 | 635.92 |
| 2021-08-02 | 655.77 |
| 2021-07-30 | 625.12 |
| 2021-07-29 | 602.76 |
| 2021-07-28 | 546.09 |
| 2021-07-27 | 532.02 |
| 2021-07-26 | 547.63 |
| 2021-07-23 | 588.11 |
| 2021-07-22 | 585.41 |
| 2021-07-21 | 552.84 |
| 2021-07-20 | 537.03 |
| 2021-07-19 | 513.71 |
| 2021-07-16 | 515.64 |
| 2021-07-15 | 516.41 |
| 2021-07-14 | 512.94 |
| 2021-07-13 | 527.20 |
| 2021-07-12 | 514.09 |
| 2021-07-09 | 535.68 |
| 2021-07-08 | 517.56 |
| 2021-07-07 | 526.24 |
| 2021-07-06 | 502.91 |
| 2021-07-02 | 489.61 |
| 2021-07-01 | 488.46 |
| 2021-06-30 | 480.94 |
| 2021-06-29 | 489.03 |
| 2021-06-28 | 474.58 |
| 2021-06-25 | 477.85 |
| 2021-06-24 | 478.43 |
| 2021-06-23 | 447.40 |
| 2021-06-22 | 424.85 |
| 2021-06-21 | 402.29 |
| 2021-06-18 | 379.35 |
| 2021-06-17 | 359.69 |
| 2021-06-16 | 363.93 |
| 2021-06-15 | 358.15 |
| 2021-06-14 | 388.61 |
| 2021-06-11 | 484.79 |
